Mesenchymal stem cells (MSCs) are multi-potent stem cells that can generate various microenvironment components in bone marrow, ensuring a precise control over self-renewal and multi-lineage differentiation of hematopoietic stem cells. Nevertheless, their spatiotemporal correlation with embryonic hematopoiesis remains rudimentary, particularly in relation to the human being.
Introduction
Mesenchymal stem cells (MSCs) are defined as a group of multi-potent stem cells that can functionally differentiate into at least bone, fat and cartilage in vitro and in vivo. [1] [2] [3] [4] [5] [6] [7] [8] Under appropriate culture conditions, MSCs are readily amplified in vitro for several passages without signs of senescence and differentiation. The two properties render them as an intriguing source in cell therapy and tissue engineering. MSCs are firstly documented by Friedenstein at an extremely low frequency within the bone marrow (BM), a canonical reservoir for a variety of stem cells. 1 Functionally, the self-renewal and differentiation of HSCs are tightly and precisely regulated by the marrow stromal milieu, a complex cellular network composed of the descendents of MSCs. For example, osteoblasts lining the bone surface can modulate the HSC expansion via Notch signaling pathway or N-cadherin / β -catenin adherens complex in vitro and in vivo. 9, 10 MSC itself can also modulate hematopoiesis in vitro through secreting a set of hematopoietic cytokines and intercellular contact. 11, 12 Systemic administration of adult or fetal tissue-derived MSCs promotes the homing and engraftment of HSCs in vivo by unknown mechanisms. [13] [14] [15] [16] Despite of our increasing understandings of MSCs in adult hematopoiesis, little is known about their developmental origin and correlation with strikingly changing blood-forming sites during embryogenesis, particularly in the human being. 17 The first wave of hematopoiesis in human is initiated during the third week in the extra-embryonic yolk sac (YS), characterized by the production of nucleated erythrocytes in situ. 18, 19 As is the case in other higher vertebrates, the second wave is characterized by de novo
For personal use only. on . by guest www.bloodjournal.org From generation of HSCs in the intra-embryonic P-Sp/AGM, followed by migration and colonizing downstream fetal liver for further maturation and amplification. [20] [21] [22] [23] Campagnoli et al. claims that human MSCs appear firstly in fetal blood at the 7th week, and later in the fetal liver and bone marrow from the 10th week. 24 Recently, Mendes et al.
reported that the mesenchymal progenitors are exclusively allocated in the mouse AGM other than YS. 25 However, the ontogeny of human MSCs in the embryonic hematopoietic tissues remains unknown.
Herein, we found that human AGM region served as a potent niche for embryonic
MSCs which were roughly identical to the bone marrow regarding general morphology, immunophenotype, triple differentiation capacity, and immunobiological feature. The expression of pluripotential-related markers (Oct-4 and Nanog) and the hematopoietic supportive activity in AGM-derived MSCs corroborated their development stage and anatomic location.
Materials and Methods

Human samples
18 human embryos at 25 to 40 days of development were obtained immediately after voluntary terminations of pregnancy induced with the RU 486 antiprogestative compound.
Human tissue collection for research purpose was approved by Research Ethics
Committees of both Institute of Basic Medical Sciences and Air Force General Hospital.
In all cases, pregnant women gave written consent for clinical procedure and research use of the embryonic tissues. Developmental age was estimated according to several 
Isolation and culture of YS-and AGM-derived mesenchymal progenitor cells
The YS and AGM were sterilely dissected in cold PBS under the microscope according to previously described. 26 In some cases, the AGM was longitudinally sub-dissected, separating the dorsal aorta with its surrounding mesenchyme (AoM) from the urogenital ridges (UGRs). The tissues were digested for one hour at 37°C with 0.1% collagenase type I (Sigma, St. Louis, MO) in PBS containing 20% fetal bovine serum (FBS, StemCell
Technologies, Vancouver, Canada) followed by repeated passages through a 26-gauge needle. Then, the cell suspensions were plated at a density of 5000 cells/cm 2 in α -MEM (Hyclone, Logan, Utah) containing 10% FBS, 100 units/ml penicillin and 100 ng/ml streptomycin (Hyclone), and 5 ng/ml of bFGF (R&D systems, Minneapolis, MN). After 48-hour incubation at 37°C in 5% CO 2 , nonadherent cells were removed by medium change. When reached about 70-80% of confluence, the adherent cells were digested with 0.25% trypsin/EDTA (Hyclone) for further expansion.
The growth kinetics was assessed by the cumulative population doubling assay as previously described over 5 passages. 27 The colony-forming unit of fibroblast (CFU-F) assay was carried out by plating cells at the density of 30 cells/well in 24-well plate. After 14 days of incubation, they were fixed with methanol followed by Wright-Giemsa staining.
Flow cytometry and immunofluorescence staining
For flow cytometry analysis, the adherent cells were harvested using 0.25% added without any exogenous cytokines and cocultured at 37°C with 5% CO2 for 6-7
weeks. The medium was half-volume replaced weekly, and the nonadherent fraction was replated in methylcellulose-based colony-forming cell (CFC) assay system: 1% methylcellulose, 30% FBS, 10% BSA, 20 ng/ml GM-CSF, 20 ng/ml IL-3, 20 ng/ml IL-6, 20 ng/ml Tpo, 3 U/ml Epo, 10 ng/ml FL, and 50 ng/ml SCF. Epo was purchased from Kirin and the other cytokines were obtained from Peprotech (London, UK). Alternatively, at the end of 7-week incubation, the bulk culture of long-term culture-initiating cells (LTC-IC) was examined by quantifying the CFC according to the manufacturer's instruction (StemCell Technologies). 
T cell proliferation assay
Reverse transcription-polymerase chain reaction (RT-PCR) analysis
Total RNA was collected using Trizol (Sigma-Aldrich). RNA was converted to cDNA and amplified according to the manufacture's instructions. Then target genes were amplified by PCR with specific primers (Table S1 ).
Phase contrast and fluorescence imaging
The images were collected using an Olympus CK2 inverted microscope (Tokyo, Japan) with 10×/0.25 NA A10PL objective, and were acquired using a Nikon Coolpix 995 camera (Tokyo, Japan). Confocal images were collected by a Nikon TE300 inverted microscope 
Molecular characterization of FACs in human YS and AGM region
Flow cytometry was used to determine whether the morphologically homogenous FACs possessed uniform surface markers. As demonstrated in Figure 2 , the culture-expanded
FACs comprised a single phenotypic population after passage 3. As for the AGM, the FACs were found to be positive for CD105 (SH2), CD73 (SH3), CD29, CD44, CD166 and HLA-ABC ( Figure 2B ). In contrast, they were negative for CD45, CD14, CD19, CD34 and CD31, indicating their non-hematopoietic and non-endothelial identity. They were also
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Differentiation potential of the AGM-and YS-derived FACs
Functional test is necessary to justify the identity of MSCs. The FACs of passage 3 with homogenous morphology and phenotype from different tissues were then replated under conditions known to induce the differentiation of adult MSCs into osteogenic, adipogenic and chondrogenic lineages. BM-derived MSCs were used as positive control.
When cultured in osteogenic-inductive medium with ascorbic acid, dexamethasone and β -glycerol phosphate, the FACs underwent a dramatic change in cellular morphology from spindle-shape to cuboidal, which was accompanied by an increased alkaline phosphatase activity ( Figure 3A) . Progressively, aggregates or nodules formed with calcium deposition as determined by von Kossa staining ( Figure 3A ). In addition, the substantial osteoblastic differentiation was shown by the mRNA expression of osteopontin (OPN) and osteocalcin (OCN) ( Figure 3D ).
To assess the adipogenic differentiation potential, the FACs were plated at the density of 5000 cells/cm 2 and cultured in medium that favored adipogenic differentiation. After 2 weeks of induction with dexamethasone, methyl-isobutylxanthine and indomethacin, Figure   3D ).
To evaluate the chondrogenic potential, 4×10 5 FACs from AGM or YS were centrifuged gently in 15-ml polypropylene tube, and the cell pellets were cultured in the serum-free chondrogenic medium containing TGF-β3 for 3 weeks. Similar to BM-derived MSCs, the AGM-derived FACs formed pelleted micromass, developing a multilayered matrix-rich morphology. The chondrocyte-like lacunae were evident in histological sections, and the extensive extracellular matrix was rich in type II collagen ( Figure 3C ), a typical marker of articular cartilage. Furthermore, the development and accumulation of cartilage matrix was shown by staining the proteoglycans with Alcian blue or Safranin-O ( Figure 3C ).
Under the same chondro-inductive medium, the FACs from YS developed a smaller spherical micromass. However, the extracelluar matrix was poor and failed to react with anti-type II collagen antibody, Alcian blue and Safranin O ( Figure 3C ). The results were consistent in 7 independent experiments, suggesting that the chondrogenic capacity of YS-derived FACs was absent in vitro. Consistently, the mRNA expression of type II collagen and aggrecan, specific genes of chondrogenesis, were detected in the differentiation cultures of AGM but not YS ( Figure 3D ).
Clonal identification of AGM-derived MSCs
Oct-4 and Nanog are taken for specific markers of human and mouse embryonic stem 28 As shown in Figure 4A , both AoM and YS derived FACs homogenously expressed Oct-4 and Nanog. In a strict sense, stem cell identification must be undertaken at a clonal level. To confirm whether the FACs contained authentic MSC populations, clonal analysis of mesenchymal potential was performed. In the first step, the colony forming potential of FACs was assessed by CFU-F assay. 30 cells from YS, AoM and UGRs (passage 3) were incubated in 24-well plate for 14 days respectively. As demonstrated in Figure 4B , the CFU-F colonies from YS appeared smaller than those from AoM or UGRs. Representative data from 3 independent experiments showed that AoM-derived FACs possessed the highest colony forming efficiency (26.7%), while that of UGRs (13.3%) and YS cells (14.4%) were much lower ( Figure 4C ). Previous finding documented the endothelial potential of mouse AGM-derived stromal cells. 34 As shown in Figure S2 , BM-and AoM-derived MSCs were able to generate capillary-like structures in Matrigel within 24 hours. Furthermore, a minority of the cells acquired the expression of CD34 and CD31, the relatively specific endothelial molecules that were absent in non-induced MSCs.
Embryonic MPCs supported hematopoiesis in vitro
To determine whether MPCs isolated from human embryos were able to regulate hematopoiesis as their adult counterparts, we performed in vitro long-term hematopoietic + cells were overlaid and maintained in long-term culture medium for 6-7 weeks without adding any exogenous cytokines. According to a previously described method, 24 weekly CFC assay was carried out on the non-adherent fraction from the culture. As show in Figure 6A , the CFCs were continuously yielded for 6 weeks in the wells with AGM-, YS-and BM-derived MPCs. On the contrary, the cultures in the wells without feeder layer failed to produce hematopoietic colonies after 1 week of incubation (data not shown).
Statistic analysis representative of 3 independent experiments showed that the CFC frequencies in the AGM group exceeded those of BM at multiple time points ( Figure 6A ).
Furthermore, the LTC-IC assay using bulk culture was carried out. After 7-week co-cultures of CD34 + cells with MPCs, the CFCs in the cultures including the adherent layers were determined. As shown in Figure 6B , there were 37.5±5.9 CFCs in the presence of AoM-MSCs, resembling those with BM-MSCs (32±3.4, P>0.05). RT-PCR assay showed that the AoM-and YS-derived MPCs expressed a set of early-acting hematopoietic cytokines including bone morphogenetic protein 4 (BMP4), TGF-β1 and FL, and lineage-specific cytokines GM-CSF except G-CSF. Generally, the data indicated that human embryonic MPCs were capable of supporting long-term hematopoiesis in vitro.
Embryonic MPCs were capable of suppressing T lymphocyte proliferation in vitro
It has been well documented that human and murine MSCs can suppress T lymphocyte proliferation in vitro when stimulated by nonspecific mitogens or allogeneic 
are capable of maintaining the long-term reconstitution activities, and the supportive properties of these stromal clones are largely retained even after induced to mature osteoblasts in vitro. 34 Most impressively, upon exposure to AGM-derived stromal cell line, the early YS-derived precursors are conferred with a capacity of long term hematopoietic reconstitution. 36 However, the external colonization of MPCs to the yolk sac appears unlikely in the mouse embryos. Despite the emergence of MPCs in the circulation at E12, the mesenchymal potential is absent in the YS at E14. 25 During mammalian embryogenesis, hematopoiesis proceeds successively within distinct cellular microenvironments such as the YS blood island, AGM mesenchyme, hepatic parenchyme, and BM primary logette, reflecting a remarkable adaptation of the developing hematopoietic system to the rapidly changing niche. 43, 44 Taken together with the evidence illustrating the mesenchymal precursor development in blood-forming tissues of both human fetus and mouse mid-gestation embryos, 24, 25 we herein propose that a 
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